Strategic Acquisition TherOx is now part of ZOLL Medical Corporation, which can streamline procurement, clinical integration, and cross-sell opportunities within a larger hospital systems network.

AMI Therapy Focus SSO2 Therapy targets acute myocardial infarction patients post-PCI, presenting a clear value proposition for interventional cardiology and cath lab teams seeking to improve infarct size outcomes.

Clinical Alignment TherOx’s therapy aligns with existing interventional cardiology guidelines, easing adoption by clinicians and potentially accelerating payer discussions and coverage considerations.

Mid-market Scale With a lean team and revenue in the lower single digits, there is room to scale through ZOLL’s enterprise channels, hospital alliances, and installed base across mid-size health systems.

Expansion Opportunities Key sales angles include integration with PCI workflows, potential adjacency to hyperbaric and perfusion services, and leveraging ZOLL’s global footprint to reach additional hospitals and procurement contracts.